Our Medical Team & Approach
At MB Stem Cells & Aesthetics, our care is built around a collaborative team of experienced physicians working within a structured and carefully developed clinical approach.
Our model is designed to ensure consistency, safety, and high standards across every patient experience. Each treatment is performed by qualified medical professionals following protocols developed through extensive training, clinical experience, and ongoing refinement.
Our focus is not only on performing procedures, but on delivering a comprehensive regenerative strategy — from patient evaluation to treatment and follow-up — with attention to detail at every step.
We prioritize quality biologics, appropriate patient selection, and individualized care plans, recognizing that meaningful outcomes require more than a one-size-fits-all approach.
This structure allows us to continue growing while maintaining the level of care and integrity our patients expect.
What is Regenerative Medicine?
Regenerative medicine represents a transformative shift in healthcare—one that focuses not just on treating symptoms, but on restoring the body’s natural ability to heal itself. By harnessing advanced biologic therapies that support cellular repair, reduce inflammation, and stimulate tissue regeneration, regenerative medicine works at the source of many chronic conditions and injuries. Instead of simply managing decline, this approach aims to rebuild, rejuvenate, and revitalize damaged tissues, helping patients recover function, relieve pain, and regain the vitality that allows them to live life fully.
Patient Stories – MB Stem Cells & Aesthetics
How are the cells acquired?
Amniotic and umbilical cord tissues are ethically sourced from healthy, consenting donors under the age of 35 who are undergoing scheduled cesarean sections. The entire process—from tissue collection to testing, processing, and storage—is strictly regulated by the FDA to ensure optimal patient safety.
Typically, during a routine scheduled C-section, materials such as the amniotic fluid, placenta, and umbilical cord—collectively known as products of conception—are discarded. In this case, however, the mother voluntarily donates these materials, and both she and the baby remain healthy and unaffected. The donated tissues are immediately placed in sterile containers and transported to a nearby FDA-registered and certified laboratory for further handling
Are all Amniotic and Umbilical Cord biologics the same?
The short answer is no—they are not all the same. Although the donor biologic material is very similar, the way it is processed can differ significantly. All donors are thoroughly screened for infectious diseases and are under the age of 35. Additionally, DNA components are removed to minimize the risk of rejection, making the biologic material immunologically privileged.
The most notable differences arise during processing at FDA-certified laboratories. While the FDA enforces strict guidelines, there is still variation in how labs handle the material. For example, some laboratories may irradiate the biologic, which destroys all living cells. Others may use excessive preservatives, which can also eliminate cell viability instead of preserving it.
As a result, not all products are equal after processing. It is essential to receive treatment from an experienced provider who uses high-quality, thoroughly vetted materials. At MB Stem Cell, we rigorously evaluate all biologics used in our treatments—one of the many reasons over 10,000 patients have trusted our Centers over the past six years.
Does Insurance cover Regenerative Treatments?
At this time, regenerative procedures are not covered by insurance. This is not due to a lack of effectiveness, but rather the complexity of insurance approval—even for FDA-approved treatments. Additionally, since amniotic fluid and umbilical cord tissue cannot be patented, pharmaceutical companies have limited incentive to push for coverage. It’s common for emerging medical technologies to take 5 to 10 years before gaining acceptance by commercial insurers and Medicare. That said, a promising development is that several states now recognize regenerative procedures as valid under Workers’ Compensation, especially because they’ve been effective in helping patients return to work.
At MB Stem Cell, we believe cost should not be a barrier to care. That’s why we offer multiple financing options and payment plans to make regenerative therapies more accessible.
Are these procedures going to Cure my Condition?
It is important to set realistic expectations. Terms like “heal” or “cure” should be avoided, as they can mislead patients and erode trust. No therapy guarantees 100% success, and while many patients do experience meaningful improvement and relief, these treatments are not cures. We’re often asked if we offer guarantees, and the honest answer is no—because no medical procedure can promise perfect results. More appropriate terms include facilitate, mitigate, or enhance.
The biologic components used in these therapies are designed to support tissue repair and activate the body’s natural healing mechanisms. However, the extent of improvement varies from person to person—because each individual is unique.
Are these Procedures FDA approved?
No, these materials are not classified as drugs. Instead, they fall under the category of biologics, which are subject to strict FDA regulation. However, unlike drugs, biologics are not approved or denied through a traditional drug approval process.
Here’s how the FDA regulates different categories:
Medical Devices – Includes items like joint implants, surgical screws, rods, and durable medical equipment (DME). In regenerative medicine, this primarily applies to kits used for PRP, bone marrow, or adipose-derived procedures.
Drugs – Examples include medications such as Lipitor, Vicodin, or Viagra. These must undergo clinical trials and FDA approval for specific indications before being made available.
Biologics – The FDA tightly oversees how biologic materials are sourced, processed, stored, and used under Code of Federal Regulations (CFR) Part 1271. Amniotic and umbilical cord-derived products fall within this category. Importantly, biologics under this classification do not go through an approval or denial process like traditional drugs.
Specifically, these materials are considered Section 361 products, which means they are not required to be licensed or formally approved by the FDA. Instead, they are regulated under Section 361 of the Public Health Service (PHS) Act, focusing on safety standards to prevent the spread of communicable diseases.